Education
About Us
Working with TipRanks
Follow Us
Mangalam Drugs & Organics Ltd. (IN:MANGALAM)
:MANGALAM
MANGALAM Stock Chart & Stats
₹30.40
-₹1.02(-0.89%)
At close: 4:00 PM EST
₹30.40
-₹1.02(-0.89%)
Day’s Range― - ―
52-Week Range₹22.70 - ₹94.80
Previous CloseN/A
Volume15.57K
Average Volume (3M)5.11K
Market Cap
₹500.49M
Enterprise Value₹1.42B
Total Cash (Recent Filing)₹25.89M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta0.85
Next Earnings
May 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.21
Shares Outstanding15,828,248
10 Day Avg. Volume11,101
30 Day Avg. Volume5,111
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)0.84
Price to Sales (P/S)0.39
P/FCF Ratio5.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialty Chemicals & API FocusA concentrated portfolio in specialty chemicals and pharmaceutical intermediates supports durable demand from drugmakers and chemical customers. B2B supply relationships and export channels can provide stable, higher-margin revenue streams versus commodity chemicals, aiding long-term resilience.
Manageable Leverage / Stable Balance SheetA balanced capital structure and manageable debt position give the company financial flexibility to fund working capital, capex and compliance investments. This stability reduces bankruptcy risk and supports operational continuity through cyclical headwinds.
Improving Operating Cash FlowImproved operating cash generation indicates better cash conversion of earnings and supports internal funding of operations and selective investments. Reliable OCF can sustain production scale-ups and working capital needs even when reported earnings fluctuate.
Bears Say
Declining Revenue And Net IncomeA large recent revenue decline and falling net income undermine the company’s ability to absorb fixed costs and invest in growth. Prolonged top-line deterioration risks market share erosion and weakens pricing power with customers and suppliers over the medium term.
Contracting EBIT/EBITDA MarginsShrinking operating margins signal pressure from input costs, product-mix shifts or inefficiencies. Sustained margin compression reduces free cash available for reinvestment, increases sensitivity to demand shocks, and limits the firm's ability to fund margin-enhancing projects.
Inconsistent Free Cash Flow & Rising DebtIrregular free cash flow plus an upward trend in total debt raises refinancing and liquidity risk if earnings stay weak. This combination constrains capital allocation, may force cost cutting, and reduces buffer for regulatory or quality-related capex required in pharma supply.
Mangalam Drugs & Organics Ltd. News
MANGALAM FAQ
What was Mangalam Drugs & Organics Ltd.’s price range in the past 12 months?
Mangalam Drugs & Organics Ltd. lowest stock price was ₹22.70 and its highest was ₹94.80 in the past 12 months.
What is Mangalam Drugs & Organics Ltd.’s market cap?
Mangalam Drugs & Organics Ltd.’s market cap is ₹500.49M.
When is Mangalam Drugs & Organics Ltd.’s upcoming earnings report date?
Mangalam Drugs & Organics Ltd.’s upcoming earnings report date is May 27, 2026 which is in 75 days.
How were Mangalam Drugs & Organics Ltd.’s earnings last quarter?
Mangalam Drugs & Organics Ltd. released its earnings results on Jan 15, 2026. The company reported -₹6.214 earnings per share for the quarter, missing the consensus estimate of N/A by -₹6.214.
Is Mangalam Drugs & Organics Ltd. overvalued?
According to Wall Street analysts Mangalam Drugs & Organics Ltd.’s price is currently Overvalued.
Does Mangalam Drugs & Organics Ltd. pay dividends?
Mangalam Drugs & Organics Ltd. pays a Notavailable dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Mangalam Drugs & Organics Ltd. dividends here
What is Mangalam Drugs & Organics Ltd.’s EPS estimate?
Mangalam Drugs & Organics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mangalam Drugs & Organics Ltd. have?
Mangalam Drugs & Organics Ltd. has 15,828,248 shares outstanding.
What happened to Mangalam Drugs & Organics Ltd.’s price movement after its last earnings report?
Mangalam Drugs & Organics Ltd. reported an EPS of -₹6.214 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Mangalam Drugs & Organics Ltd.?
Currently, no hedge funds are holding shares in IN:MANGALAM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Mangalam Drugs & Organics Ltd.
Mangalam Drugs & Organics Limited manufactures and sells drugs, medicines, and allied products in India and internationally. It offers a range of active pharmaceutical ingredients, intermediates, and specialty chemicals, as well as impurities for use in anti-malarial, analgesic/anti-inflammatory, anti-hypertensive, and anti-retroviral applications. The company was incorporated in 1972 and is based in Mumbai, India.
Technical Analysis
Bhageria Industries Ltd.
―
Ganesh Benzoplast Limited
―
HP Adhesives Ltd.
―
Khaitan Chemicals & Fertilizers Ltd.
―
Mangalam Organics Ltd
―